Safety approval VP-001, page-3

Next cohort (#2) is medium dose, followed by #3 cohort which will be high dose.

In PYC's June '23 Investor Update presentation, page 14, provides some interesting info on patient derived models, (patient organoids), which points towards safety and efficacy in a good way. PYC also makes reference to wishing to know likely outcomes before expensive clinical trials get underway.

For me personally, I like PYC's approach, they seem to have their ducks lined up very strategically and whilst nothing is completely free of risk, I feel they are progressively ticking the right boxes as they move forward and have taken as much risk off the table as they can for the stage they are at.

https://hotcopper.com.au/threads/ann-pyc-investor-update-presentation.7432807/